CRVS Corvus Pharmaceuticals, Inc. Insider Trading

Director David Scott Moore buys 21,700 shares of CRVS at $11.53; stock down 55.8% from 52-week high amid ongoing losses.

Director David Scott Moore purchased 21,700 shares at $11.53 on 2026-06-11, establishing a non-derivative position of 21,700 shares while retaining 15,000 shares in stock options (Table II derivative holdings). The buy occurs in a depressed context: the stock trades 55.8% below its 52-week high of $26.95, down 23.0% over the prior 90 days, and the company posted a net loss of $-13.7M in its most recent full fiscal year. The purchase represents a material commitment ($250.2K) by a director into a company experiencing significant revenue headwinds and unprofitability, suggesting directional conviction at current valuation levels. With derivative holdings intact, this represents a selective accumulation of non-derivative equity rather than a blanket portfolio bet, and the 90-day decline provides the context for this entry timing.

CEO Richard A Md Miller purchases 6,932 shares for $83,453.32 at CRVS amid -54.8% decline from 52-week high and -$13.7M net loss.

Richard A Md Miller, President and CEO of Corvus Pharmaceuticals, executed 2 separate purchases totaling 6,932 shares for $83,453.32 on 2026-05-18, increasing his holdings to 1,195,035 shares. The blended average purchase price of $12.04 falls significantly below the 52-week high of $26.95, with the stock currently trading at $12.19, -54.8% from its 52-week peak and down -21.6% over the past 30 days. The company reported a net loss of $-13,692,000.00 over its most recent fiscal year, and the CEO's purchase occurs in a context of sustained equity decline. While this represents an open-market acquisition by the company's chief executive, the modest scale (+0.6% vs pre-transaction holdings) and the broader operating losses provide limited basis for interpreting this as a strong affirmative signal about near-term prospects.